scholarly journals Characteristics of a Chronic Cough Population Participating in Two Large Phase III Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist

2021 ◽  
Author(s):  
P. Dicpinigaitis ◽  
L. McGarvey ◽  
A.H. Morice ◽  
J. Smith ◽  
S.S. Birring ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Receptor Antagonist ◽  
Chronic Cough ◽  
Phase Iii ◽  
P2x3 Receptor ◽  
Phase Iii Clinical Trials ◽  
Large Phase

scholarly journals TREATMENT OF REFRACTORY OR UNEXPLAINED CHRONIC COUGH WITH GEFAPIXANT, A P2X3 RECEPTOR ANTAGONIST, OVER 52 WEEKS IN TWO PHASE III CLINICAL TRIALS

CHEST Journal ◽  
2021 ◽  
Vol 160 (4) ◽  
pp. A2361-A2362
Author(s):  
Peter Dicpinigaitis ◽  
Surinder Birring ◽  
Alyn Morice ◽  
Jaclyn Smith ◽  
Lorcan McGarvey ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Receptor Antagonist ◽  
Chronic Cough ◽  
Phase Iii ◽  
P2x3 Receptor ◽  
Two Phase ◽  
Phase Iii Clinical Trials

Rome I versus Rome II; Overlap in patients enrolled in tegaserod phase III clinical trials for irritable bowel syndrome (IBS)

2001 ◽  
Vol 120 (5) ◽  
pp. A284-A284
Author(s):  
B NAULT ◽  
S SUE ◽  
J HEGGLAND ◽  
S GOHARI ◽  
G LIGOZIO ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Irritable Bowel Syndrome ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Irritable Bowel ◽  
Rome I

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

2001 ◽  
Vol 28 (6) ◽  
pp. 620-625 ◽  
Author(s):  
Pierre Falardeau ◽  
Pierre Champagne ◽  
Patrick Poyet ◽  
Claude Hariton ◽  
[Eacute]ric Dupont
Keyword(s):  
Clinical Trials ◽  
Phase Iii ◽  
Phase Iii Clinical Trials ◽  
Naturally Occurring ◽  
Antiangiogenic Drug

scholarly journals Animal and Human Vaccines against West Nile Virus

Pathogens ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1073
Author(s):  
Juan-Carlos Saiz
Keyword(s):  
Clinical Trials ◽  
West Nile Virus ◽  
Vaccine Development ◽  
Phase Iii ◽  
West Nile ◽  
Specific Therapy ◽  
Phase Iii Clinical Trials ◽  
Neuroinvasive Disease ◽  
The Us ◽  
The Status

West Nile virus (WNV) is a widely distributed enveloped flavivirus transmitted by mosquitoes, which main hosts are birds. The virus sporadically infects equids and humans with serious economic and health consequences, as infected individuals can develop a severe neuroinvasive disease that can even lead to death. Nowadays, no WNV-specific therapy is available and vaccines are only licensed for use in horses but not for humans. While several methodologies for WNV vaccine development have been successfully applied and have contributed to significantly reducing its incidence in horses in the US, none have progressed to phase III clinical trials in humans. This review addresses the status of WNV vaccines for horses, birds, and humans, summarizing and discussing the challenges they face for their clinical advance and their introduction to the market.

Sign in / Sign up

Export Citation Format

Share Document